The Stroke Feasibility Study Will Evaluate the AtriClip for Stroke Prevention in Atrial Fibrillation Patients
AtriCure’s AtriClip left atrial appendage device will be evaluated for preventing strokes in patients with nonvalvular atrial fibrillation who cannot take anticoagulants
By Mellanie True Hills and Melissa Moss
June 26, 2014
- Summary: The Stroke Feasibility Study will evaluate the AtriClip left atrial appendage device for stroke prevention in atrial fibrillation
- Reading time: 1–2 minutes
The Stroke Feasibility Study, launched by AtriCure, will assess the safety and effectiveness of the AtriClip Left Atrial Appendage Exclusion System in reducing strokes in afib patients who are unable to take anticoagulants.
The AtriClip is applied to the left atrial appendage of the heart during a minimally invasive surgical procedure. The left atrial appendage is the source of more than 90 percent of afib-related blood clots. The Stroke Feasibility Study will determine the effectiveness of the AtriClip in reducing strokes in patients with non-valvular atrial fibrillation.
To learn more about the AtriClip and the Stroke Feasibility Study, including who is eligible and what centers are participating, see: